ABSTRACT

Despite of the advances in the treatment of cardiovascular diseases and in the treatment of chronic heart failure, ageing of the population cause a rapid increase in the prevalence of chronic heart failure in the population. Several factors have role in the etiology of heart failure including congenital factors. By understanding the molecular mechanisms in the etiology, new powerful agents were found in the treatment of heart failure. Vascular endothelial growth factor (VEGF) and HIF 1 were the angiogenic factors, used in clinical phase II analyses successfully. The preliminary results in angiogenic therapy and gene therapy in heart failure are hopeful.